apidra 100 unitsml solution for injection in vial
sanofi-aventis singapore pte. ltd. - insulin glulisine - injection, solution - 3.49 mg - insulin glulisine 3.49 mg
zaltrap concentrate for solution for infusion 25 mgml
sanofi-aventis singapore pte. ltd. - aflibercept - infusion, solution concentrate - 25.0 mg/ml - aflibercept 25.0 mg/ml
podevta solution for injection in cartridge 100 unitsml
sanofi-aventis singapore pte. ltd. - insulin glargine - injection, solution - 100units/ml(10.9134mg/3ml) - insulin glargine 100units/ml(10.9134mg/3ml)
lyxumia
sanofi-aventis new zealand limited - lixisenatide 0.05 mg/ml; lixisenatide 0.1 mg/ml - solution for injection - 0.05mg/ml + 0.1mg/ml - active: lixisenatide 0.05 mg/ml excipient: glycerol hydrochloric acid metacresol methionine sodium acetate sodium hydroxide water for injection active: lixisenatide 0.1 mg/ml excipient: glycerol hydrochloric acid metacresol methionine sodium acetate sodium hydroxide water for injection - lyxumia is indicated for the treatment of adults with type 2 diabetes mellitus to achieve glycaemic control in combination with metformin, metformin and sulphonylurea, basal insulin and metformin, basal insulin and sulphonylurea when these, together with diet and exercise, do not provide adequate glycaemic control (see sections clinical trials and precautions) (risk of hypoglycemia) for available data on the different combinations.
lyxumia
sanofi-aventis new zealand limited - lixisenatide 0.05 mg/ml - solution for injection - 0.05 mg/ml - active: lixisenatide 0.05 mg/ml excipient: glycerol hydrochloric acid metacresol methionine sodium acetate sodium hydroxide water for injection - lyxumia is indicated for the treatment of adults with type 2 diabetes mellitus to achieve glycaemic control in combination with metformin, metformin and sulphonylurea, basal insulin and metformin, basal insulin and sulphonylurea when these, together with diet and exercise, do not provide adequate glycaemic control (see sections clinical trials and precautions) (risk of hypoglycemia) for available data on the different combinations.
lyxumia
sanofi-aventis new zealand limited - lixisenatide 0.1 mg/ml - solution for injection - 0.1 mg/ml - active: lixisenatide 0.1 mg/ml excipient: glycerol hydrochloric acid metacresol methionine sodium acetate sodium hydroxide water for injection - lyxumia is indicated for the treatment of adults with type 2 diabetes mellitus to achieve glycaemic control in combination with metformin, metformin and sulphonylurea, basal insulin and metformin, basal insulin and sulphonylurea when these, together with diet and exercise, do not provide adequate glycaemic control (see sections clinical trials and precautions) (risk of hypoglycemia) for available data on the different combinations.
lantus solostar 100iuml solution for injection in a pre-filled pen
sanofi-aventis (malaysia) sdn. bhd. - insulin glargine -
apidra solostar 100 unitsml solution for injection in a pre-filled pen
sanofi-aventis (malaysia) sdn. bhd. - insulin glulisine -
soliqua solostar 100unitsml+33mcgml solution for injection in a pre-filled pen
sanofi-aventis (malaysia) sdn. bhd. - insulin glargine; lixisenatide -
soliqua solostar 100unitsml+50mcgml solution for injection in a pre-filled pen
sanofi-aventis (malaysia) sdn. bhd. - insulin glargine; lixisenatide -